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Abstract
Background: Increases in the number of salmonellosis cases due to Salmonella Enteritidis (SE) in 2010 and 2011
prompted a public health investigation in Ontario, Canada. In this report, we describe the current epidemiology of
travel-related (TR) SE, compare demographics, symptoms and phage types (PTs) of TR and domestically-acquired
(DA) cases, and estimate the odds of acquiring SE by region of the world visited.
Methods: All incident cases of culture confirmed SE in Ontario obtained from isolates and specimens submitted to
public health laboratories were included in this study. Demographic and illness characteristics of TR and DA cases
were compared. A national travel survey was used to provide estimates for the number of travellers to various
destinations to approximate rates of SE in travellers. Multivariate logistic regression was used to estimate the odds
of acquiring SE when travelling to various world regions.
Results: Overall, 51.9% of SE cases were TR during the study period. This ranged from 35.7% TR cases in the
summer travel period to 65.1% TR cases in the winter travel period. Compared to DA cases, TR cases were older and
were less likely to seek hospital care. For Ontario travellers, the adjusted odds of acquiring SE was the highest for
the Caribbean (OR 37.29, 95% CI 17.87-77.82) when compared to Europe. Certain PTs were more commonly
associated with travel (e.g., 1, 4, 5b, 7a, Atypical) than with domestic infection. Of the TR cases, 88.9% were
associated with travel to the Caribbean and Mexico region, of whom 90.1% reported staying on a resort. Within this
region, there were distinct associations between PTs and countries.
Conclusions: There is a large burden of TR illness from SE in Ontario. Accurate classification of cases by travel
history is important to better understand the source of infections. The findings emphasize the need to make
travellers, especially to the Caribbean, and health professionals who provide advice to travellers, aware of this risk.
The findings may be generalized to other jurisdictions with travel behaviours in their residents similar to Ontario
residents.
Background
Salmonella bacteria are estimated to cause 93.8 million
cases of gastroenteritis and 155,000 deaths worldwide
each year, with 2,800 of these deaths estimated to occur
in North America [1]. In the last decade, the rate of
reported cases of Salmonella enterica subsp. enterica ser-
ovar Enteritidis (SE) has increased steadily in Ontario.
For the years 2000 to 2004, the average annual number
of SE cases was 502 [2-5]. Following a large outbreak of
SE in 2005, the average annual number was 710 cases
for the years 2006 to 2009 [6-8]. In 2010, the number
increased further to 1,035 cases, which prompted the
investigation of SE illnesses in the province of Ontario
[9]. A hypothesis-generating study was undertaken which
identified several food items that were subsequently tested
with a separate, unpublished case–control study.
In 2006, the estimated mean cost per case of gastro-
enteritis in Ontario was CAN $1,089 and the mean an-
nual cost per capita was CAN $115 [10]. This represents
a substantial and preventable burden of illness as well as
a cost to the health care system. While surveillance of
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borne infection is standard practice, less is known about
the epidemiology of travel-related (TR) enteric patho-
gens, and in particular TR SE. Variable proportions of
cases of reported salmonellosis associated with inter-
national travel have been documented in several studies.
Two Canadian studies estimated that the minority of
Salmonella cases, ranging from 27% to 38%, were due to
travel [11,12]. Another study from the United States
(USA) identified 11% of Salmonella cases to be TR [13].
The significance of TR SE has been noted in Europe with
a Danish study finding 25% of cases of SE to be TR be-
tween 1997 and 1999, and a Swedish study attributing
78% of Salmonella with TR status between 1997 and
2003 [14,15]. The number of TR cases by region or
country of travel, without appropriate denominator in-
formation on travel patterns, may be more reflective of
travel patterns than risk. Therefore, in order to assess
the risk of SE associated with travel to different countries
and regions, we used information collected during the
hypothesis-generating study described above and subse-
quent case control study, along with a population-based
travel survey to obtain denominator information. In this
report, we compare demographics, symptoms and phage
types (PTs) of TR and DA cases in order to describe the
current epidemiology of TR SE in Ontario residents. Fur-
ther, we estimate the risk of acquiring SE by region of
the world visited.
Methods
Setting
Ontario is Canada’s largest province, consisting of 13.2
million residents in 2010 [16]. Ontario’s public health
system consists of 36 health units responsible for the
delivery of local public health programs, as well as one
central and 10 regional public health laboratories oper-
ated by Public Health Ontario.
Laboratory testing and methods
The public health laboratories serve as the reference
centre for enteric bacteria in Ontario. The services pro-
vided include the primary isolation of enteric pathogens to
support outbreak investigations, as well as reference iden-
tification, serotyping and molecular typing of enteric
pathogens submitted from hospital and private laborator-
ies. Salmonella spp. isolates from across the province are
sent to the public health laboratories for serotyping based
on the Kauffmann –White scheme [17]. As per routine
practice, all isolates identified as SE are forwarded to the
National Microbiology Laboratory in Winnipeg for phage
typing using methods described by Ward and colleagues
[18]. The laboratory and PT results are compiled daily at
the Toronto public health laboratory and shared with the
investigators in a line list format.
Case ascertainment and data collection
We interviewed all incident cases with culture confirmed
SE submitted to the Toronto public health laboratory
during two investigation stages: a hypothesis-generating
stage from July 11
th to November 30
th, 2010 and a case–
control study stage from January 20
th to July 31
st, 2011.
(The case–control study is a separate, unpublished study
not described here. The purpose of the case–control
study was to identify risk factors for DA cases. The con-
trols used in the case–control study were healthy con-
trols randomly selected from the Ontario population).
Cases were excluded who: resided outside of Ontario or
on a First Nations reserve; had SE isolated from a clinical
specimen other than stool; had testing performed more
than two months following symptom onset; or could not
speak English. Additionally, only the first specimen was
included for cases that had repeated specimens pur-
posely performed. For this study, we also excluded cases
with a symptom onset date prior to July 2010, during
December 2010, and after June 2011. Cases were lost to
follow-up if they died, did not have a telephone number
available, or could not be reached following five attempts.
Refusals were defined as those cases who declined to be
interviewed.
We performed telephone interviews using two stan-
dardized questionnaires (one for each study stage) that
collected demographic, clinical symptom, and travel in-
formation in a similar manner. The questionnaires also
collected animal contact, food exposure, and food-
hygiene practice information that was modified between
the hypothesis-generating and case–control study stage
based on the hypotheses generated. Parents or guardians
responded on behalf of children less than 16 years of age.
All respondents gave informed verbal consent prior to
beginning the interview. Ethical approval was not required
to interview cases because this was a public health investi-
gation under the Ontario Health Protection and Promo-
tion Act [19]. Data from questionnaires were entered into
EpiData version 3.1 (Lauritsen JM & Bruus M. EpiData
Entry).
A TR case was defined as an Ontario resident, with
culture confirmed SE and a symptom onset date between
July 2010 and June 2011 (excluding December 2010),
who travelled outside of Canada within the three days
prior to onset of illness. A DA case was defined as an
Ontario resident, with culture confirmed SE identified
and a symptom onset date between July 2010 and June
2011 (excluding December 2010), who did not travel out-
side of Canada in the three days prior to onset of illness.
The time period from July to October 2010 and May to
June 2011 was classified as the “summer travel period”,
and the month of November 2010 and the time period
from January to April 2011 were classified as the “winter
travel period”. In order to generate total Ontario SE case
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proximate symptom onset date for cases who were lost
to follow-up using the date their sample was received at
the laboratory minus the average number of days from
symptom onset date to the date received at the labora-
tory for interviewed cases. The percent of travel cases by
month was calculated by dividing the number of TR
cases by the number of interviewed cases per month.
Comparison of travel-related (TR) and domestically-
acquired (DA) cases
TR and DA cases were compared to determine differ-
ences in demographics, health-seeking behaviour and ill-
ness characteristics using Wilcoxon rank-sum tests for
continuous variables and chi-squared tests for categorical
variables. We used logistic regression, comparing TR to
DA cases, to examine the effect of adjusting for age for
each covariate group. Recovery time was calculated as
symptom end date minus symptom onset date. For cases
whose symptoms were on-going at the time of interview,
a minimum recovery period was calculated as the inter-
view date minus the symptom onset date.
Salmonella Enteritidis (SE) risks associated with travel
The Statistics Canada International Travel Survey was
used as a source of denominator data for travel patterns
for Ontario residents. The year 2009 was the most recent
complete year of data available from this survey at the
time of analysis [20]. Respondents of this survey were
obtained from a simple random sample of the total num-
ber of travellers through port of entry by yearly quarter.
We extracted information from 7,826 interviews, account-
ing for 16,870 travellers, for this analysis. Data on principal
country of travel, age, gender, travel start-date and travel
end-date were used for this analysis. Data on illness were
not available in this dataset. For respondents visiting mul-
tiple countries during one trip, we used the first country
where the respondent had spent two or more nights as
the principal country, excluding those that did not spend
at least two nights in a single destination abroad. We
excluded those who returned from their travels during
time intervals where case data were not collected (i.e.,
November 16 to January 7). Using a weighting system
developed by Statistics Canada for the International
Travel Survey, we determined the estimated number of
international travellers among Ontario residents. For re-
gression analyses, we included only those travellers with
a principal travel country other than the USA (1,708
interviews, representing 3,710 travellers) as “controls”.
The USA was excluded from these analyses since there
were only two TR SE cases that travelled to the USA,
and inclusion of this small number would have yielded
unstable regression parameter error estimates.
We developed two multivariate logistic regression
models using a manual, forward stepwise selection ap-
proach including variables significant at the P≤0.05
level. We designed our logistic regression analysis based
on the study conducted by Ekdahl et al. [15]. We used
TR SE as cases and International Travel Survey travellers
as “controls” to estimate the odds of infection in 1) dif-
ferent world regions and in 2) Caribbean countries and
Mexico. We tested age, sex and travel period (summer
vs. winter) for possible confounding and effect modifica-
tion in both models. The final models presented include
only statistically significant (P≤0.05) covariates of the
risk of acquiring SE from travel to a particular region or
country.
Data analyses were conducted using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA), STATA version 10.1
(Statacorp, TX, USA) and SPSS version 19 (SPSS Inc., an
IBM Company).
Results
There were a total of 998 laboratory-confirmed cases
during the study period. Of the 998 cases, 165 (16.5%)
cases met our exclusion criteria, leaving 833 cases. Of
the 833 cases, 209 (25.1%) were either lost to follow-up
or refused to participate, resulting in 624 cases included
in this analysis. Thus, the response rate for this study
was calculated as 74.9% (624/833). The response rate
varied by investigation stage (Stage 1: 62.0% (204/329);
Stage 2: 83.3% (420/504)). Cases lost to follow-up and
refusals compared to those included in the analysis did
not differ with respect to age (P=0.105), however, cases
lost to follow-up and refusals were more likely to be
male (P=0.035) and identified during Stage 1 of the
study collection period (P<0.0001).
Of the 624 cases in this study, 324 (51.9%) were TR
cases and 300 (48.1%) were DA. Figure 1 presents the
number of eligible cases and the proportion of inter-
viewed SE cases in a given month that were TR. In the
winter travel period (November, and January to April),
the proportion of TR cases was 65.1%, while in the sum-
mer travel period (May-October), 35.7% of cases were TR.
Comparison of travel-related (TR) and domestically-
acquired (DA) Salmonella Enteritidis (SE) cases
The illness characteristics of TR and DA cases, exam-
ined via symptoms and recovery time revealed one sig-
nificant difference: a higher proportion of TR cases
reported experiencing nausea than DA cases (66.4% vs.
51.7%, P<0.001), which remained significant after
adjusting for age (OR 1.86, 95% CI 1.25 to 2.50). All
other symptoms were reported in similar proportions
for TR and DA cases. While TR cases reported a longer
minimum recovery time (11 days vs. 9 days, P=0.004),
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1.02, 95% CI 0.99 to 1.04).
The demographic characteristics and health-seeking
behaviour of TR and DA cases are presented in Table 1.
TR cases were older, with a median age of 35 years com-
pared to 21 years among DA cases (P<0.001). Signifi-
cantly fewer TR cases visited the Emergency Room and
were admitted to the hospital than DA cases (P=0.003
and P<0.001, respectively). Both of these associations
were independent of age (OR 0.58, 95% CI 0.41 to 0.82
and OR 0.31, 95% CI 0.16 to 0.57, respectively).
Salmonella Enteritidis (SE) risks associated with travel to
various world regions and countries
Two cases were excluded as they had reported visiting
multiple world regions. Of the remaining 322 TR cases,
283 (88.9%) were acquired in the Caribbean and Mexico
region (Table 2). Of these 283 cases, 268 (94.7%) travelled
to five countries: Dominican Republic, Cuba, Jamaica,
Mexico and Antigua. Further, of the 283 cases that trav-
elled to this region, 255 (90.1%) stayed on a resort. The
median travel duration was 7.0 days (Inter-quartile range
7.0 to 8.0).
The lowest risk of TR SE cases per 100,000 was for tra-
vellers to the USA (0.03) and Europe (0.63) and the high-
est risk was for travellers to the Caribbean and Mexico
Region (24.11) (Table 2). The highest odds of being a TR
SE case was for those who had travelled to the Caribbean
(OR 37.29, 95% CI 17.87 to 77.82) when controlling for
the effect of age and the travel period compared to cases
who had travelled to Europe (Table 3). In the Caribbean/
Mexico region, Antigua, Jamaica and Barbados had the
Figure 1 Salmonella Enteritidis infections, by symptom onset month and percent travel-related July 2010 to June 2011. *Data are
incomplete for November 2010 and January 2011, given the study period start and end dates. The total number of eligible cases includes both
interviewed cases (n=624) and cases lost to follow-up (n=202). Symptom onset dates are estimated for lost to follow-up cases based on the
mean delay (12 days) from symptom onset date to laboratory received date for interviewed cases. The percent travel cases by month was
calculated by dividing the number of TR cases by the number of interviewed cases per month.
Table 1 Demographic characteristics and health-seeking
behaviour of domestically-acquired (n=300) and travel-
related (n=324) cases of Salmonella Enteritidis
Travel Domestic Total P value*
n%n % n%
Age (median)
Median (yrs) 35 21 <0.001
0–11 51 15.7 93 31.0 144 23.1
12–19 25 7.7 47 15.7 72 11.5
20–34 83 25.6 64 21.3 147 23.6
35–54 105 32.4 54 18.0 159 25.5
55–64 40 12.3 17 5.7 57 9.1
65+ 20 6.2 25 8.3 45 7.2
Male** 175 54.2 153 51.3 328 52.6 0.479
Symptoms
}
Diarrhea 320 99.4 291 98.0 611 98.7 0.124
Abdominal Cramps 280 88.3 252 86.9 532 87.6 0.686
Nausea 213 66.4 152 51.7 365 59.4 <0.001
Vomiting 127 39.7 116 39.3 243 39.5 0.926
Fever 219 68.4 217 73.1 436 70.7 0.523
Other 214 68.2 183 62.5 397 65.4 0.140
Visited Emergency Room† 105 33.4 131 45.2 236 36.8 0.003
Admitted to hospital{ 16 5.1 45 15.2 61 10.0 <0.001
*Chi-squared test p-value; **Three cases missing sex (2 DA, 1 TR). } Five cases
were missing diarrhea (3 DA, 2 TR) data, 17 abdominal cramps (10 DA, 7 TR), 9
nausea (6 DA, 3 TR), 9 vomiting (5 DA, 4 TR), 7 fever (3 DA, 4 TR); and 17 other
(7DA, 10TR). † Twenty cases missing emergency-room information (10 TR, 10
DA); {Fourteen cases missing admission to hospital information (11 TR, 3 DA).
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17.28 (95% CI 9.29 to 32.13) and 13.18 (95% CI 2.96 to
58.69), respectively, compared to Mexico when adjusting
for age and travel period.
Travel characteristics and phage type (PT) distributions by
common travel destination among travel-related cases
The distribution of PTs for SE cases by travel status is
shown in Figure 2. PTs 8, 1 and 13a were the three
most frequently detected PTs during our study period,
accounting for 62.2% of all cases. The majority of cases
with PTs 7a, 1, 5b, Atypical and 4 reported travel ex-
posure, while cases with PTs 8, 13a, 13, 22, 21c, and 51
were predominantly DA.
Examination of the PT distributions from TR cases
returning from the five most commonly visited countries
revealed a distinct PT distribution (Table 4). PT 1 accounted
for 88.9% of the cases who travelled to the Dominican
Republic, PT 5b accounted for 58.4% of the cases return-
ing from Cuba, PT 7a accounted for 47.1% of the cases
returning from Mexico, and PT 13a and 8 were the two
most common PTs isolated from travellers to Jamaica
(56.6% PT 13a and 35.8% PT 8) and Antigua (46.2% PT 8
and 53.8% PT 13a).
Discussion
During the investigation period, 51.9% of SE cases in
Ontario were TR. This finding was surprising to us as
unpublished Reportable Disease data by Vrbova et. al.,
indicated that the proportion of TR cases for salmonellosis
was approximately 20%. This finding was consistent,
however, with a 2010 publication of findings from a sub-
population of Ontario. Of the SE cases identified in the
Region of Waterloo, 48.7% were classified as TR for the
period June 2005 - May 2009 [11]. In our study, the TR
SE cases occurred predominately in the winter months
when more Ontario residents travel to “sun” destinations.
Previously, similar findings pertaining to TR cases and
seasonality were found in the province of British Columbia
[12]. Separating TR and DA cases in analyses of SE surveil-
lance data facilitates identifying relevant trends and poten-
tial clusters for investigation.
The number of SE cases in Ontario was 1,035 in 2010
and the estimated population was 13,227,800 [9,16]. Thus,
the rate of SE cases in Ontario in 2010 was 7.82 per
100,000 persons. The rates of SE per 100,000 travellers for
the Caribbean and Mexico region (24.11), Antigua (74.57),
Cuba (26.75), Dominican Republic (29.14), and Jamaica
(92.23) were markedly higher than the overall rate for
Ontario. In contrast, the SE rates for travellers to the
USA (0.03) and Europe (0.63) were lower than the overall
rate for Ontario. Regression analysis revealed some statis-
tically significant findings. The odds of acquiring SE for
travellers to the Caribbean were 37 times greater than for
travellers to Europe. Further, the odds of acquiring SE in
the Caribbean were significantly higher than the odds of
acquiring SE for travellers to Asia and Mexico. Among
travellers to the Caribbean and Mexico region specifically,
there were five countries (i.e., Antigua, Jamaica, Barbados,
Dominican Republic, and Cuba) for which the odds of
Table 2 Distribution of travel-related Salmonella Enteritidis cases by world region, and by Caribbean/Mexico region
Travel region/country Estimated no. of travelers† Controls† Reported cases†† Rate/100 000
Africa 108,486 75 6 5.53
Asia 419,489 449 15 3.58
Caribbean and Mexico 1,173,785 1,682 283 24.11
Antigua 17,433 16 13 74.57
Cuba 287,797 418 77 26.75
Dominican Republic 370,653 549 108 29.14
Jamaica 57,465 78 53 92.23
Mexico 254,160 418 17 6.69
Other* 186,277 203 15 8.05
Central America 85,476 112 4 4.68
Europe 1,267,932 1,240 8 0.63
Oceania 26,521 52 1 3.77
South America 106,769 100 3 2.81
USA 5,920,574 13,160 2 0.03
Total 9,109,032 16,870 322 3.53
† Number of travellers is estimated based on the number of survey respondents (controls) from the 2009 Statistics Canada International Travel Survey.
††Two cases (0.6%) were excluded from this analysis because they had visited multiple world regions.
*“Other” includes Bahamas, Barbados. Bermuda, Cayman Islands, St. Kitts, St. Lucia, St. Vincent, Trinidad & Tobago, Turks & Caicos, British Virgin Islands, Dutch West
Indies, Guadeloupe, Haiti, Puerto Rico, US Virgin Islands, and West Indies N.E.S.
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Unadjusted Adjusted*
OR 95% CI OR 95% CI
World Region Analysis (Cases: 318, Controls: 3,454)†
Region
Europe Ref - Ref -
Africa 12.40 4.20–36.66 14.01 4.68–41.91
Asia 5.18 2.18–12.30 6.41 2.67–15.41
Central America 5.54 1.64–18.67 5.85 1.71–20.03
Caribbean 32.37 15.95–65.70 37.29 17.87–77.82
North America (Mexico only) 6.30 2.70–14.71 6.89 2.86–16.60
Oceania 2.98 0.37–24.28 3.68 0.45–30.25
South America 4.65 1.22–17.80 5.71 1.48–22.08
Age (years)
0–11 9.53 5.50–16.49 7.85 4.37–14.13
12–19 3.22 1.75–5.92 2.36 1.25–4.46
20–34 3.60 2.18–5.96 2.31 1.37–3.90
35–54 2.32 1.42–3.79 1.61 0.97–2.66
55–64 1.31 0.75–2.29 1.08 0.61–1.91
65+ Ref - Ref -
Travel Period: “Winter” 0.50 0.39 – 0.65 1.31 0.98–1.74
Caribbean Country and Mexico Sub-Analysis (Cases: 279, Controls: 1,489){
Country
Mexico Ref - Ref -
Cuba 4.53 2.63–7.79 4.75 2.73–8.25
Dominican Republic 4.84 2.86–8.19 5.00 2.92–8.56
Jamaica 16.71 9.19–30.36 17.28 9.29–32.13
Antigua 19.98 8.30–48.07 19.63 7.78–49.52
Curacao 1.12 0.25–5.00 1.50 0.33–6.91
Bahamas 2.20 0.78–6.18 2.02 0.70–5.85
Barbados 12.29 2.83–53.38 13.18 2.96–58.69
St. Lucia 8.20 0.81–82.95 6.59 0.64–68.44
Age (years)
0–11 5.35 2.91–9.83 5.75 3.02–10.95
12–19 2.10 1.08–4.08 2.39 1.20–4.77
20–34 2.12 1.23–3.63 1.78 1.01–3.14
35–54 1.42 0.84–2.39 1.28 0.74–2.20
55–64 0.80 0.44–1.48 0.80 0.43–1.50
65+ Ref – Ref –
Travel Period: “Winter” 1.83 1.36–2.46 1.35 0.96–1.89
*The adjusted odd ratios (ORs) presented are each adjusted for all of the other significant variables in the model (i.e. age category, travel period, and region or
country).
† Of the total 324 cases, there were 6 cases excluded because of the following: two visited multiple world regions, two travelled to the USA, and two visited
multiple countries within the Caribbean; of the total 3,710 controls, 256 were excluded because of missing age.
{ Of the total 283 cases who travelled to the Caribbean and Mexico, 4 cases were excluded because of the following: two visited multiple countries within the
Caribbean, and two cases were excluded because they travelled to Grenada and there were no controls who had travelled to Grenada; of the total 1,682 controls
who travelled to the Caribbean and Mexico, 99 were excluded because of missing age, and 94 were excluded because no cases visited their respective countries:
Bermuda (6), St. Kitts (4), St. Vincent (3), Trinidad & Tobago (29), Turks & Caicos Is. (1), British Virgin Islands (1), Guadeloupe (29), Haiti (1), Puerto Rico (15), West
Indies, N.E.S. (5).
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The degree to which the rates in the various travel desti-
nations change from year to year is not known. Nonethe-
less, having a good understanding of the rates in the
travellers to different parts of the world would assist
those providing advice to prospective travellers to those
regions with a higher risk of acquiring illness. Freedman
et. al., found that only 30% of travellers to the Caribbean
sought pre-travel medical advice which was less than the
55% of travellers seeking advice for travelling to other
developing regions [21]. This might indicate that travel-
lers believe the health risks associated with the Caribbean
are less than those associated with other travel destina-
tions in the developing world.
The Caribbean countries and Mexico are well known
winter travel destinations for Ontario residents, in part,
because of the numerous “all-inclusive” resorts. For this
reason, Mexico was grouped with the Caribbean a priori.
Our data showed that 88.9% of reported TR illnesses
were acquired in this region. Further, our data revealed
that 90.1% of all SE cases travelling to the Caribbean and
Mexico region had stayed at a resort. Given the high per-
centage of SE cases that travelled to the Caribbean and
who stayed at a resort, further investigation should be
considered in regard to the role that these resorts have
in being a source of illness. While our investigation only
considered SE, further investigation should also be consid-
ered in regard to the role of the Caribbean and resorts for
other enteric pathogens. A recent study of a Canadian
community by Ravel et. al., reported that 25% of Campylo-
bacter,1 3 %o fGiardia, 66% of non-typhoidal Salmonella,
44% of Shigella, and 89% of Yersiniosis TR cases stayed at
a resort [11].
Identifying both the Salmonella serotypes and PTs can
be instrumental for identifying sources of infection for
sporadic and outbreak cases [22,23]. In our investigation,
we also made use of the PT findings by making associa-
tions with the travel status of a case. In Ontario, prior to
this investigation, there were three PTs that were thought
to be most frequently DA (i.e., PT 8, 13 and 13a). Other
PTs were thought to be most frequently TR (i.e., 1, 4, and
5b). There were other PTs, especially newly identified and
infrequently identified PTs, for which the TR or DA asso-
ciation was not well understood (e.g., Atypical, 21c, 51).
The investigation improved our knowledge of the associ-
ation between travel and PTs. We learned that there were
a higher percentage of TR PT 8 and PT 13a cases than
previously thought, although these PTs remain predomin-
antly DA, and that these TR cases occurred primarily in
the winter consistent with the winter travel period. We
also confirmed our understanding that PTs, 1, 4, and 5b
were TR although we did learn that there was a small
percentage of these PTs that were acquired in Ontario.
Improvements in the quality of Reportable Disease data
would assist with improving the capability to assess the
TR status of the various PTs.
Our investigation also revealed that there were distinct
associations between various PTs and the five most fre-
quently visited countries, i.e., Antigua and Jamaica – PT 8
and 13, Cuba – PT 5b, Dominican Republic – PT 1, and
Mexico PT 7a. It is not known whether these associations
are consistent from year to year. Further investigation in
Figure 2 Comparison of phage types between domestically-acquired (n=300) and travel-related (n=324) cases of Salmonella
Enteritidis. *Other phage types include those with 7 or fewer cases.
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tries is warranted. These associations may assist with iden-
tifying the source of the illnesses, possibly in regard to the
consumption of imported and domestically obtained food
items.
Limitations
The purpose of the original study was to identify the
source of the increase of SE in Ontario using a hypothesis-
generating stage to inform the subsequent case–control
study. Thus, the original study design was not intended
to consider detailed characteristics of TR cases. Fur-
ther, for logistical reasons, in the transition between
the hypothesis-generating stage and the case–control
stage, case interviews were discontinued from December
1, 2010 to January 19, 2011. Certainly, having the data for
this omitted period would have been useful for continuity.
The definition of a TR case was a person who travelled
outside of Canada within the three days prior to onset of
illness. Misclassification of TR cases may occur with this
definition resulting in an over-estimation of TR illness.
For example, cases with onset of illness soon after depart-
ure, or cases with illness onsets two or three days after
return, may have acquired their illness in Ontario. If we
reclassified the nine cases in this study who had a symp-
tom onset date within one day of travel departure and
the 44 cases with illness onsets two or three days follow-
ing their return, the proportion of travel-related cases
would decrease by less than 10% from 51.9% to 43.4%.
Data on illness was not collected on the traveller
respondents in the Statistics Canada International Travel
Survey. Therefore, it is possible that this control group
could include some cases. However, using the highest
rate we found in travellers, we would expect three cases
at most to have been misclassified as controls, and hav-
ing included them in our analysis would have biased our
results toward the null. Another limitation was that con-
trols for the various travel destinations were obtained
from 2009 data, since 2010 and 2011 data were not avail-
able at the time of writing. While it is unlikely that large
changes in travel patterns occurred between 2009 and
2010–11, such changes would impact both our rate cal-
culations and our logistic regression results, especially
for smaller destinations in the Caribbean.
Conclusion
Our investigation into the source of an increase in SE
cases in Ontario led to the finding that TR cases repre-
sent a considerable burden of SE illness in Ontario. A
large majority of the TR SE cases were acquired while
staying at a resort in the Caribbean and Mexico region.
For Ontario travellers to various destinations in the
world, the odds of acquiring SE were the highest for the
Caribbean.
Collectively, these findings would prove useful to other
jurisdictions with travel patterns in their residents similar
to Ontario residents. Having a good understanding of
whether cases were TR or DA is useful for understanding
the source and risk of infections as well as trends in sur-
veillance data. The findings would also be useful for
those involved with providing health advice to travellers
to the Caribbean. Finally, the travel destinations identi-
fied that were associated with contracting SE contribute
Table 4 Distribution of phage types for the five most
common travel destinations among travel-related
Salmonella Enteritidis cases
Country and phage
type
2010* 2011** Total
n% n% n %
Antigua
13a 0 0.0 6 46.2 6 46.2
8 0 0.0 7 53.8 7 53.8
Total 0 - 13 100.0 13 100.0
Cuba
4 2 8.3 2 3.8 4 5.2
5b 18 75.0 27 50.9 45 58.4
8 1 4.2 2 3.8 3 3.9
Atypical 2 8.3 21 39.6 23 29.9
Other
1 1 4.2 1 1.9 2 2.6
Total 24 100.0 53 100.0 77 100.0
Dominican Republic
1 14 100.0 82 87.2 96 88.9
53 0 0 2 2.1 2 1.9
5b 0 0 2 2.1 2 1.9
8 0 0 3 3.2 3 2.8
Other
2 0 0 5 5.3 5 4.6
Total 14 100.0 94 100.0 108 100.0
Jamaica
13a 5 50.0 25 58.1 30 56.6
8 5 50.0 14 32.6 19 35.8
2 0 0.0 2 4.7 2 3.8
Other
3 0 0.0 2 4.7 2 3.8
Total 10 100.0 43 100.0 53 100.0
Mexico
7a 2 66.7 6 42.9 8 47.1
21 0 0.0 2 14.3 2 11.8
Other
4 1 33.3 6 42.9 7 41.2
Total 3 100.0 14 100.0 17 100.0
* - specimen collection date July 11 to November 30, 2010.
** - specimen collection date January 20 to July 31, 2011.
Other phage types were grouped if only one positive case for that phage type
was recorded:
1: PTs 27 and 29a;
2: PTs 1b, 4, 6a, 13, and 37;
3: PTs 22 and 51;
4:
PTs 1, 6, 6a, 8, 18, 22, and 41.
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SE.
Abbreviations
DA: Domestically acquired; PT: Phage type; SE: Salmonella Enteritidis;
TR: Travel related; USA: United States of America.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
The authors wish to acknowledge; the Ontario Ministry of Health and
Long-Term Care for providing funding for the investigation, the SE cases
who consented to participate in the investigation, staff at Ontario health
units for their cooperation, Lisa Hansen for reviewing the manuscript, Ali
Moterassed for performing the phage typing work, other members of the
SE Investigation Working Group including Tina Badiani, Jackson Chung, Lisa
Fortuna, Karen Johnson, Allison McArthur, Sarah Morgan, Beata Pach, Duri
Song, Diana Yung, and finally David Northrup at the Institute for Social
Research for their involvement interviewing controls.
Author details
1Public Health Ontario, 480 University Ave, Toronto, M5G 1V2, Canada.
2Canadian Field Epidemiology Program, Public Health Agency of Canada, 8
Colonnade Road, Ottawa, Ontario K2E 7M6, Canada.
3Guy’s, King’s and St
Thomas’ School of Medicine, London SE1 9RT, UK.
4School of Population and
Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC
V6T 1Z3, Canada.
5Ontario Ministry of Health and Long-Term Care, 1075 Bay
St, Toronto, Ontario M5S 2B1, Canada.
6Department of Population Medicine,
University of Guelph, Guelph, Ontario N1G 2 W1, Canada.
7Dalla Lana School
of Public Health, University of Toronto, 155 College St., Health Sciences
Building, 6th Floor, Toronto, Ontario M5T 3 M7, Canada.
8Laboratory
Medicine and Pathobiology, University of Toronto, Toronto, Canada.
9National
Microbiology Laboratory, Public Health Agency of Canada, Ottawa, Canada.
Authors’ contributions
DM, CV and YW conceived of the study. MKT, RS, LV, RW, CV, BL, YW and DM
developed the study design and methodology. MKT, RS, RW, and CJ were
involved with interviewing cases. MKT, RS, MT, LV, and BD were involved
with data management and analysis. VA, AM, and RA were involved in
laboratory analysis. MKT, RS, MT, LV, VA, RW, CV, BL, BD, NC, and DM were
involved with drafting the manuscript. All authors read and approved the
final manuscript.
Received: 21 December 2011 Accepted: 26 April 2012
Published: 26 April 2012
References
1. Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O’Brien SJ, Jones TF, Fazil
A, Hoekstra RM: The global burden of nontyphoidal Salmonella
gastroenteritis. Clin Infect Dis 2010, 50:882–889.
2. Public Health Agency of Canada.Laboratory Surveillance Data For Enteric
Pathogens In Canada: Annual Summary 2000. Ottawa; 2001.
3. Public Health Agency of Canada.Laboratory Surveillance Data For Enteric
Pathogens In Canada: Annual Summary 2001. Ottawa; 2004.
4. Public Health Agency of Canada.Laboratory Surveillance Data For Enteric
Pathogens In Canada: Annual Summary 2002 and 2003. Ottawa; 2005.
5. Public Health Agency of Canada.Laboratory Surveillance Data For Enteric
Pathogens In Canada. Annual Summary 2004. Ottawa; 2006.
6. Public Health Agency of Canada.Laboratory Surveillance Data For Enteric
Pathogens In Canada: Annual Summary 2005. Ottawa; 2007.
7. Public Health Agency of Canada.Laboratory Surveillance Data For Enteric
Pathogens In Canada: Annual Summary 2006. Ottawa; 2007.
8. Public Health Agency of Canada, Provincial Public Health Microbiology
Laboratories.National Enteric Surveillance Program (NESP): Annual Summary
2009. Ottawa; 2010.
9. Public Health Agency of Canada, Provincial Public Health Microbiology
Laboratories.National Enteric Surveillance Program (NESP): Annual Summary
2010. Ottawa; 2010.
10. Majowicz SE, McNab WB, Sockett P, Henson TS, Doré K, Edge VL, Buffett MC,
Fazil A, Read S, McEwen S, Stacey D, Wilson JB: Burden and cost of
gastroenteritis in a Canadian community. J Food Prot 2006, 69:651–659.
11. Ravel A, Nesbitt A, Marshall B, Sittler N, Pollari F: Description and burden of
travel-related cases caused by enteropathogens reported in a Canadian
community. J Travel Med 2011, 18:8–19.
12. Taylor M, MacDougall L, Li M, Galanis E, BC Enteric Policy Working Group*:
The impact of international travel on the epidemiology of enteric
infections, British Columbia, 2008. Can J Public Health 2010, 101:332–336.
13. Johnson LR, Gould LH, Dunn JR, Berkelman R, Mahon BE, Foodnet Travel
Working Group: Salmonella infections associated with international travel:
a Foodborne Diseases Active Surveillance Network (FoodNet) study.
Foodborne Pathog Dis 2011, 8:1031–1037.
14. Molbak K, Niemann J: Risk factors for sporadic infection with Salmonella
enteritidis, Denmark, 1997–1999. Am J Epidemiol 2002, 156:654–661.
15. Ekdahl K, de Jong B, Wollin R, Andersson Y: Travel-associated non-typhoidal
salmonellosis: geographical and seasonal differences and serotype
distribution. Clin Microbiol Infect 2005, 11:138–144.
16. Statistics Canada: Population by year, by province and territory. [http://www40.
statcan.ca/l01/cst01/demo02a-eng.htm]
17. Health Protection Agency: Kauffmann-White Scheme - 2007. London:; 2007.
18. Ward LR, de Sa JD, Rowe B: A phage-typing scheme for Salmonella
Enteritidis. Epidemiol Infect 1987, 99:291–294.
19. Health Protection and Promotion Act R.S.O. 1990 H.7. 1990 Part VI.1,
77.6 (1)-77.6 (7).
20. Statistics Canada: International Travel Survey. Ottawa: Minister of Industry;
2010.
21. Freedman DO, Weld LH, Kozarsky PE, Fisk T, Robins R, von Sonnenburg F,
Keystone JS, Pandey P, Cetron MS: Spectrum of disease and relation to
place of exposure among ill returned travelers. N Engl J Med 2006,
354:119–130.
22. Voetsch AC, Poole C, Hedberg CW, Hoekstra RM, Ryder RW, Weber DJ,
Angulo FJ: Analysis of the FoodNet case–control study of sporadic
Salmonella serotype Enteritidis infections using persons infected with
other Salmonella serotypes as the comparison group. Epidemiol Infect
2009, 137:408–416.
23. Welby S, Imberechts H, Riocreux F, Bertrand S, Dierick K, Wildemauwe C,
Hooyberghs J, Van der Stede Y: Comparison of Salmonella Enteritidis
Phage Types isolated from Layers and Humans in Belgium in 2005.
Foodborne Pathog Dis 2011, 8:929–934.
doi:10.1186/1471-2458-12-310
Cite this article as: Tighe et al.: The epidemiology of travel-related
Salmonella Enteritidis in Ontario, Canada, 2010–2011. BMC Public Health
2012 12:310.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tighe et al. BMC Public Health 2012, 12:310 Page 9 of 9
http://www.biomedcentral.com/1471-2458/12/310